AMENDMENTS TO THE SPECIFICATION

Amend the specification by adding before the first line the sentence:

This is a U.S. national stage of Application No. PCT/JP2004/004554 filed March 30, 2004.

Please replace the paragraph bridging pages 4 to 14, specifically line 18 on page 14, with the following amended paragraph:

One aspect of the present invention relates to certain substituted heterocyclic compounds represented by Formula (I):



(I)

wherein Q is:



(IIa) ,  **(IIb)** or  **(IIc)**

R^1 is selected from the group consisting of:

(i) C_{1-8} alkyl, and

C_{1-8} alkyl substituted by substituent(s) independently selected from the group consisting of:

•oxo,

•halogen,

•C_{1-5} alkoxy carbonyl,

•C_{1-5} alkoxy,

•C_{1-5} alkoxy substituted by carbocyclic aryl,

•mono-C_{1-5} alkylamino,

•mono-C_{1-5} alkylamino substituted by carbocyclic aryl,

•di-C_{1-5} alkylamino,

•di-C_{1-5} alkylamino substituted by carbocyclic aryl,

•C_{1-5} alkylthio,

•C_{3-6} cycloalkyl,

•C_{3-6} cycloalkyl substituted by C_{1-5} alkyl,

•C_{3-6} cycloalkenyl,

•carbocyclyl,

•carbocyclic aryl,

•carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:

••hydroxy,

••halogen,

••nitro,

••amino,

••C_{1-5} alkylcarbonylamino,

••C_{3-6} cycloalkylcarbonylamino,

••carbocyclic aryl,

••C_{1-5} alkyl,

••C_{1-5} alkyl substituted by halogen,

••C_{1-5} alkylsulfonyl,

••C_{2-6} alkenyl,

••C_{1-5} alkoxy, and

••C_{1-5} alkoxy substituted by halogen,

•mono-carbocyclic arylamino,

•mono-carbocyclic arylamino substituted by substituent(s) independently selected from the group consisting of:

••halogen,

••C_{1-5} alkyl,

••C_{1-5} alkyl substituted by halogen,

••C_{1-5} alkoxy, and

••C_{1-5} alkoxy substituted by halogen,

•di-carbocyclic arylamino,

•di-carbocyclic arylamino substituted by substituent(s) independently selected from the group consisting of:

••halogen,

••C_{1-5} alkyl,

••C_{1-5} alkyl substituted by halogen,

••C_{1-5} alkoxy, and

••C_{1-5} alkoxy substituted by halogen,

•carbocyclic aryloxy,

•carbocyclic aryloxy substituted by substituent(s) independently selected from the group consisting of:

••halogen,

••C_{1-5} alkyl,

••C_{1-5} alkyl substituted by halogen,

••C_{1-5} alkoxy,

••C_{1-5} alkoxy substituted by halogen, and

••carbocyclic aryl,

•hydroxy,

•heterocyclyl, and

•heterocyclyl substituted by halogen,

(ii) C_{2-5} alkenyl, and

C_{2-5} alkenyl substituted by substituent(s) independently selected from the group consisting of:

•oxo, and

•carbocyclic aryl,

(iii) C_{2-5} alkynyl,

(iv) C_{3-12} cycloalkyl, and

C_{3-12} cycloalkyl substituted by carbocyclic aryl,

(v) carbocyclyl, and

carbocyclyl substituted by substituent(s) independently selected from the group consisting of:

•hydroxy, and

•carbocyclic aryl,

(vi) carbocyclic aryl, and

carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:

•halogen,

•cyano,

•nitro,

•amino,

•C_{1-10} alkyl,

•C_{1-10} alkyl substituted by substituent(s) independently selected from the group consisting of:

••halogen,

••oxo, and

••carbocyclic aryl,

•carboxy,

•C_{1-5} alkoxy carbonyl,

•C_{1-7} alkoxy,

•C_{1-7} alkoxy substituted by substituent(s) independently selected from the group consisting of:

••halogen, and

••carbocyclic aryl,

•C_{3-6} cycloalkoxy,

•carbocyclic aryloxy,

•carbocyclic aryloxy substituted by substituent(s) independently selected from the group consisting of:

••halogen,

••nitro,

••C_{1-5} alkyl,

••C_{1-5} alkyl substituted by halogen,

••C_{1-5} alkoxy, and

••C_{1-5} alkoxy substituted by halogen,

•heterocyclyloxy,

•heterocyclyloxy substituted by substituent(s) independently selected from the group consisting of:

••halogen,

••nitro,

••C_{1-5} alkyl,

••C_{1-5} alkyl substituted by halogen,

••C_{1-5} alkoxy, and

••C_{1-5} alkoxy substituted by halogen,

•mono-C_{1-5} alkylamino,

•di-C_{1-5} alkylamino,

•C_{1-5} alkylcarbonylamino,

•C_{3-6} cycloalkylcarbonylamino,

•C_{1-5} alkoxy carbonylamino,

•carbocyclic aryl azo,

•carbocyclic aryl azo substituted by substituent(s) independently selected from the group consisting of:

••mono-C_{1-5} alkylamino, and

••di-C_{1-5} alkylamino,

•C_{1-5} alkylthio,

•C_{1-5} alkylthio substituted by halogen,

•carbocyclic arylthio,

•carbocyclic arylthio substituted by nitro,

•amino sulfonyl,

•heterocyclyl sulfonyl,

•C_{3-6} cycloalkyl,

•C_{3-6} cycloalkyl substituted by C_{1-5} alkyl,

•carbocyclic aryl,

•carbocyclic aryl substituted by C_{1-5} alkoxy,

•hydroxy,

•heterocyclyl, and

•heterocyclyl substituted by C_{1-5} alkyl,

(vii) heterocyclyl, and

heterocyclyl substituted by substituent(s) independently selected from the group consisting of:

•halogen,

•C_{1-5} alkyl,

•C_{1-5} alkyl substituted by halogen,

•C_{1-5} alkoxy,

•C_{1-5} alkoxy substituted by halogen,

•C_{1-5} alkoxy carbonyl,

•C_{1-5} alkoxy carbonyl substituted by carbocyclic aryl,

•carbocyclic aryloxy,

•carbocyclic aryloxy substituted by substituent(s) independently selected from the group consisting of:

••halogen,

••nitro,

••cyano,

••hydroxy,

••C_{1-5} alkyl,

••C_{1-5} alkyl substituted by halogen,

••mono-C_{1-5} alkylamino,

••di-C_{1-5} alkylamino,

••C_{1-5} alkylcarbonylamino,

••C_{3-6} cycloalkylcarbonylamino,

••C_{1-5} alkoxy,

••C_{1-5} alkoxy substituted by halogen,

••C_{3-6} cycloalkyl,

••C_{2-5} alkenyl,

••C_{2-5} alkynyl,

••carboxy,

••C_{1-5} alkoxycarbonyl,

••mono-C_{1-5} alkylaminocarbonyl,

••di-C_{1-5} alkylaminocarbonyl,

••mono-C_{3-6} cycloalkylaminocarbonyl,

••di-C_{3-6} cycloalkylaminocarbonyl,

••mono-C_{1-5} alkylaminocarbonylamino,

••di-C_{1-5} alkylaminocarbonylamino,

••mono-C_{3-6} cycloalkylaminocarbonylamino,

••di-C_{3-6} cycloalkylaminocarbonylamino,

••C_{1-5} alkylthio,

••C_{1-5} alkylthio substituted by halogen,

••C_{1-5} alkylsulfinyl,

••C_{1-5} alkylsulfinyl substituted by halogen,

••C_{1-5} alkylsulfonyl, and

••C_{1-5} alkylsulfonyl substituted by halogen,

•heterocyclyloxy,

•heterocyclyloxy substituted by substituent(s) independently selected from the group consisting of:

••halogen,

••nitro,

••C_{1-5} alkyl,

••C_{1-5} alkyl substituted by halogen,

••C_{1-5} alkoxy, and

••C_{1-5} alkoxy substituted by halogen,

•carbocyclic aryl, and

•heterocyclyl;

R_2 is C_{1-5} alkyl or $-N(R_{2a})(R_{2b})$; wherein R_{2a} and R_{2b} are independently hydrogen or C_{1-5} alkyl;

R_3 is C_{1-5} alkyl;

R_4 is $-NHNH_2$, -NHNHBoc, $-N(R_{4a})(R_{4b})$, morpholino, 4-acetyl-piperazyl, or 4-phenyl-piperazyl; wherein R_{4a} is hydrogen or C_{1-5} alkyl; R_{4b} is C_{1-5} alkyl, C_{1-5} alkyl substituted by substituent(s) independently selected from the group consisting of:

•hydroxy,

•C_{1-5} alkoxy,

•amino,

•-NHBoc,

•C_{3-6} cycloalkyl,

•carbocyclic aryl,

•carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:

••halogen,

••C_{1-5} alkyl,

••C_{1-5} alkoxy, and

••$-SO_2NH_2$, and

•heterocyclyl,

C_{3-6} cycloalkyl, carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:

•halogen,

•C_{1-5} alkyl,

•C_{1-5} alkoxy, and

a group of Formula **(III)**:



(III) ;

wherein Boc is carbamic acid *tert*-butyl ester and G is C_{1-5} alkyl or C_{1-5} alkyl substituted by substituent(s) independently selected from the group consisting of:

•carbocyclic aryl,

•halogenated carbocyclic aryl, and

•carbocyclic aryl substituted by C_{1-5} alkoxy;

L is selected from the group consisting of Formulae **(IV)** to **(XIX)**:



(IV)



(V)



(VI)



(VII)



(VIII)



(IX)



(X)



(XI)



(XII),



(XIII),



(XIV),



(XV),



(XVI),



(XVII),



(XVIII),



(XIX);

wherein R_5 and R_6 are independently hydrogen or C_{1-5} alkyl; and A and B are independently a single bond, $-CH_2-$, or $-(CH_2)_2-$;

X_1, X_2, X_3 and X_4 are independently selected from the group consisting of hydrogen, halogen, C_{1-4} alkyl, C_{1-4} alkyl substituted by halogen, C_{1-4} alkylthio, C_{1-4} alkylsulfinyl, C_{1-4} alkylsulfonyl, C_{1-4} alkoxy, C_{1-4} alkoxy substituted by halogen, nitro, amino, mono-C_{1-4} alkylamino, di-C_{1-4} alkylamino, piperidyl, morpholinyl, mono-C_{1-4} alkylaminosulfonyl, di-C_{1-4} alkylaminosulfonyl and hydroxy; provided that at least one substituent selected from the group consisting of X_1, X_2, X_3 and X_4 is not hydrogen; and

Y is selected from the group consisting of:

(i) $-C(O)NR_7-$, $-C(S)NR_7-$, or $-C(O)O-$ when L is selected from the group consisting of Formulae (**IV**) to (**XIX**); wherein R_7 is hydrogen or C_{1-5} alkyl;

(ii) $-S(O)_2-$, $-C(O)-$, a single bond or $-CH_2-$ when L is selected from the group consisting of Formulae (**IV**) to (**XI**), and Q is Formula (**IIa**) or (**IIb**);

(iii) $-S(O)_2-$, -C(O)-, a single bond or $-CH_2-$ when L is selected from the group consisting of Formulae (**VII**) to (**XI**), and Q is Formula (**IIc**); and

(iv) -OC(O)- when L is selected from the group consisting of Formulae (**XII**) to (**XIX**);

wherein carbocyclic aryl is phenyl, naphthyl, or biphenyl;

carbocyclyl is indanyl, bicyclo[2.2.1]heptyl, bicyclo[2.2.1]heptenyl, ~~adamantly~~adamantyl, 9*H*-fluorenyl, menthyl, 1,2,3,4-tetrahydro-naphthalen-1-yl, or 1*H*-indolyl;

heterocyclyl is 2,3-dihydro-benzo[1,4]dioxinyl, 3,4-dihydro-2*H*-benzo[b][1,4]dioxepinyl, 4,5,6,7-tetrahydro-benzo[b]thienyl, 4*H*-benzo[1,3]dioxinyl, benzo[1,3]dioxolyl, benzo[2,1,3]thiadiazolyl, benzothiazolyl, furyl, isoxazolyl, morpholinyl, oxazolyl, piperidyl, pyrazolyl, pyridyl, tetrahydrofuryl, thienyl, dibenzofuranyl, 1*H*-benzoimidazolyl, or thiazolyl; and

halogen is fluoro, chloro, bromo, or iodo;

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

Please replace the paragraph bridging pages 17-21, specifically line 19 on page 21, with the following amended paragraph:

In some embodiments of the present invention, Q is Formulae **(IIa)**, **(IIb)**, or **(IIc)**;

R_1 is selected from the group consisting of:

(i) C_{1-8} alkyl, and

C_{1-8} alkyl substituted by substituent(s) independently selected from the group consisting of:

•halogen,

•C_{1-5} alkoxy carbonyl,

•C_{1-5} alkoxy,

•C_{1-5} alkoxy substituted by carbocyclic aryl,

•mono-C_{1-5} alkylamino,

•di-C_{1-5} alkylamino,

•C_{3-6} cycloalkyl,

•C_{3-6} cycloalkenyl,

•carbocyclyl,

•carbocyclic aryl,

•carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:

••hydroxy,

••halogen,

••nitro,

••C_{1-5} alkylcarbonylamino,

••C_{3-6} cycloalkylcarbonylamino,

••C_{1-5} alkyl,

••C_{1-5} alkyl substituted by halogen,

••C_{1-5} alkylsulfonyl,

••C_{2-6} alkenyl,

••C_{1-5} alkoxy,

••C_{1-5} alkoxy substituted by halogen, and

••carbocyclic aryl,

•heterocyclyl, and

•heterocyclyl substituted by halogen,

(ii) C_{2-5} alkenyl, and

C_{2-5} alkenyl substituted by carbocyclic aryl,

(iii) C_{2-5} alkynyl,

(iv) C_{3-12} cycloalkyl, and

C_{3-12} cycloalkyl substituted by carbocyclic aryl,

(v) carbocyclyl, and

carbocyclyl by substituent(s) independently selected from the group consisting of:

•hydroxy, and

•carbocyclic aryl,

(vi) carbocyclic aryl, and

carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:

•halogen,

•cyano,

•nitro,

•C_{1-10} alkyl,

•C_{1-10} alkyl substituted by substituent(s) independently selected from the group consisting of:

••halogen,

••oxo, and

••carbocyclic aryl,

•carboxy,

•C_{1-5} alkoxy carbonyl,

•C_{1-7} alkoxy,

•C_{1-7} alkoxy substituted by substituent(s) independently selected from the group consisting of:

••halogen, and

••carbocyclic aryl,

•carbocyclic aryloxy,

•carbocyclic aryloxy substituted by nitro,

•mono-C_{1-5} alkylamino,

•di-C_{1-5} alkylamino,

•C_{1-5} alkoxy carbonylamino,

•carbocyclic aryl azo,

•carbocyclic aryl azo substituted by substituent(s) independently selected from the group consisting of:

••mono-C_{1-5} alkylamino, and

••di-C_{1-5} alkylamino,

•C_{1-5} alkylthio,

•C_{1-5} alkylthio substituted by halogen,

•carbocyclic arylthio,

•carbocyclic arylthio substituted by nitro,

•amino sulfonyl,

•heterocyclyl sulfonyl,

•C_{3-6} cycloalkyl,

•C_{3-6} cycloalkyl substituted by C_{1-5} alkyl,

•carbocyclic aryl,

•heterocyclyl, and

•heterocyclyl substituted by C_{1-5} alkyl,

(vii) heterocyclyl, and

heterocyclyl substituted by substituent(s) independently selected from the group consisting of:

•halogen,

•C_{1-5} alkyl,

•C_{1-5} alkyl substituted by halogen,

•C_{1-5} alkoxy,

•C_{1-5} alkoxy carbonyl,

•C_{1-5} alkoxy carbonyl substituted by carbocyclic aryl,

•carbocyclic aryloxy,

•carbocyclic aryl, and

•heterocyclyl;

R_2 is $-N(R_{2a})(R_{2b})$, wherein R_{2a} is hydrogen or C_{1-5} alkyl; R_{2b} is C_{1-5} alkyl;

R_3 is C_{1-5} alkyl;

R_4 is $-N(R_{4a})(R_{4b})$ wherein R_{4a} is hydrogen or C_{1-5} alkyl; R_{4b} is C_{1-5} alkyl;

L is selected from Formula **(V)**, **(VIII)**, **(IX)**, **(XIII)**, **(XVI)**, or **(XVII)**;

X_1, X_2, X_3 and X_4 are independently selected from the group consisting of hydrogen, halogen, and C_{1-4} alkyl; provided that at least one substituent selected from the group consisting of X_1, X_2, X_3 and X_4 is not hydrogen; and

Y is selected from the group consisting of:

(i) $-C(O)NR_7-$, $-C(S)NR_7-$, or $-C(O)O-$ when L is selected from the group consisting of Formula **(V)**, **(VIII)**, **(IX)**, **(XIII)**, **(XVI)**, or **(XVII)**; wherein R_7 is hydrogen or C_{1-5} alkyl;

(ii) $-S(O)_2-$, $-C(O)-$, a single bond or $-CH_2-$ when L is selected from the group consisting of Formula **(VIII)** or **(IX)**; and

(iii) $-OC(O)-$ when L is selected from the group consisting of Formula **(XIII)**, **(XVI)**, or **(XVII)**;

wherein carbocyclic aryl is phenyl or naphthyl;

carbocyclyl is indanyl, bicyclo[2.2.1]heptyl, bicyclo[2.2.1]heptenyl, ~~adamantly~~adamantyl, 9*H*-fluorenyl, menthyl, 1,2,3,4-tetrahydro-naphthalen-1-yl, or 1*H*-indolyl;

heterocyclyl is 2,3-dihydro-benzo[1,4]dioxinyl, 3,4-dihydro-2*H*-benzo[b][1,4]dioxepinyl, 4,5,6,7-tetrahydro-benzo[b]thienyl, 4*H*-benzo[1,3]dioxinyl, benzo[1,3]dioxolyl, benzo[2,1,3]thiadiazolyl, benzothiazolyl, furyl, isoxazolyl, morpholinyl, oxazolyl, piperidyl, pyrazolyl, pyridyl, tetrahydrofuryl, thienyl, dibenzofuranyl, 1*H*-benzoimidazolyl, or thiazolyl; and

halogen is fluoro, chloro, bromo, or iodo;

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

Please replace the paragraph bridging pages 22 to 24, specifically line 10 on page 24, with the following amended paragraph:

In some embodiments of the present invention, R_1 is selected from the group consisting of:

(i) C_{1-5} alkyl, and

C_{1-5} alkyl substituted by substituent(s) independently selected from the group consisting of:

•C_{1-5} alkoxy carbonyl,

•carbocyclic aryl,

•carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:

••halogen,

••C_{1-5} alkyl,

••C_{2-5} alkenyl, and

••C_{1-5} alkoxy,

•C_{1-5} alkylthio, and

•heterocyclyl,

(ii) C_{3-6} cycloalkyl, and

C_{3-6} cycloalkyl substituted by carbocyclic aryl,

(iii) carbocyclyl,

(iv) carbocyclic aryl, and

carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:

•halogen,

•cyano,

•nitro,

•C_{1-5} alkyl,

•C_{1-5} alkyl substituted by substituent(s) independently selected from the group consisting of:

••halogen,

••oxo, and

••carbocyclic aryl,

•C_{1-5} alkoxy carbonyl,

•C_{1-7} alkoxy,

•C_{1-7} alkoxy substituted by substituent(s) independently selected from the group consisting of:

••halogen, and

••carbocyclic aryl,

•cycloalkoxy,

•carbocyclic aryloxy,

•mono-C_{1-5} alkylamino,

•di-C_{1-5} alkylamino,

•C_{1-5} alkylthio,

•C_{1-5} alkylthio substituted by halogen,

•carbocyclic aryl,

•heterocyclyl, and

•heterocyclyl substituted by C_{1-5} alkyl,

(v) heterocyclyl, and

heterocyclyl substituted by substituent(s) independently selected from the group consisting of:

•halogen,

•C_{1-5} alkyl,

•C_{1-5} alkyl substituted by halogen,

•C_{1-5} alkoxy carbonyl

•C_{1-5} alkoxy carbonyl substituted by carbocyclic aryl, and

•carbocyclic aryl;

L is Formula (V);

and

Y is $-C(O)NR_7-$; wherein R_7 is hydrogen or C_{1-5} alkyl;

wherein carbocyclic aryl is phenyl or naphthyl;

carbocyclyl is indanyl, ~~adamantly~~adamantyl, or 9*H*-fluorenyl;

heterocyclyl is 2,3-dihydro-benzo[1,4]dioxinyl, 3,4-dihydro-2*H*-benzo[b][1,4]dioxepinyl, 4*H*-benzo[1,3]dioxinyl, benzo[1,3]dioxolyl, benzothiazolyl, furyl, isoxazolyl, piperidyl, pyridyl, or thienyl; and

halogen is fluoro, chloro, bromo, or iodo;

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

Please replace the paragraph bridging pages 50 to 53, specifically line 10 on page 53, with the following amended paragraph:

In some of the embodiments of the present invention, R_1 is selected from the group consisting of:

(i) C_{1-8} alkyl, and

C_{1-8} alkyl substituted by substituent(s) independently selected from the group consisting of:

•mono-C_{1-5} alkylamino,

•di-C_{1-5} alkylamino,

•C_{3-6} cycloalkyl,

•C_{3-6} cycloalkenyl,

•carbocyclic aryl,

•carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:

••halogen,

••C_{1-5} alkyl, and

••C_{1-5} alkoxy,

•heterocyclyl,

(ii) C_{2-5} alkynyl,

(iii) C_{2-5} alkenyl, and

C_{2-5} alkenyl substituted by carbocyclic aryl,

(iv) C_{3-12} cycloalkyl,

(v) carbocyclyl,

(vi) carbocyclic aryl, and

carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:

•halogen,

•cyano,

•nitro,

•C_{1-10} alkyl,

•C_{1-10} alkyl substituted by substituent(s) independently selected from the group consisting of:

••halogen, and

••oxo,

•carboxy,

•C_{1-5} alkoxy carbonyl,

•C_{1-5} alkoxy,

•C_{1-5} alkoxy substituted by substituent(s) independently selected from the group consisting of:

••halogen, and

••carbocyclic aryl,

•carbocyclic aryloxy,

•carbocyclic aryloxy substituted by nitro,

•mono-C_{1-5} alkylamino,

•di-C_{1-5} alkylamino,

•C_{1-5} alkoxy carbonylamino,

•carbocyclic aryl azo,

•carbocyclic aryl azo substituted by substituent(s) independently selected from the group consisting of:

••mono-C_{1-5} alkylamino, and

••di-C_{1-5} alkylamino,

•C_{1-5} alkylthio,

•C_{1-5} alkylthio substituted by halogen,

•carbocyclic arylthio,

•carbocyclic arylthio substituted by nitro,

•amino sulfonyl,

•heterocyclyl sulfonyl,

•C_{3-6} cycloalkyl,

•C_{3-6} cycloalkyl substituted by C_{1-5} alkyl,

•carbocyclic aryl, and

•heterocyclyl,

(vii) heterocyclyl, and

heterocyclyl substituted by substituent(s) independently selected from the group consisting of:

•C_{1-5} alkyl,

•C_{1-5} alkoxy carbonyl,

•carbocyclic aryloxy,

•carbocyclic aryl, and

•heterocyclyl;

L is Formula (V); and

Y is -C(S)NR_7-; wherein R_7 is hydrogen or C_{1-5} alkyl;

wherein carbocyclic aryl is phenyl or naphthyl;

carbocyclyl is indanyl, bicyclo[2.2.1]heptyl, bicyclo[2.2.1]heptenyl, or ~~adamantly~~adamantyl;

heterocyclyl is 2,3-dihydro-benzo[1,4]dioxinyl, 4,5,6,7-tetrahydro-benzo[b]thienyl, benzo[1,3]dioxolyl, benzo[2,1,3]thiadiazolyl, furyl, isoxazolyl, morpholinyl, oxazolyl, piperidyl, pyrazolyl, pyridyl, tetrahydrofuryl, or thienyl; and

halogen is fluoro, chloro, bromo, or iodo;

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

Please replace the last paragraph on page 266 with the following amended paragraph:

293 cells (human kidney, ATCC), transiently transfected with 10 µg~~ug~~ human **MCH** receptor and 60 µl~~ul~~ Lipofectamine (per 15-cm dish), are grown in the dish for 24 hours (75% confluency) with a media change and removed with 10 ml/dish of Hepes-EDTA buffer (20mM Hepes + 10 mM EDTA, pH 7.4). The cells are then centrifuged in a Beckman Coulter centrifuge for 20 minutes, 17,000 rpm (JA-25.50 rotor). Subsequently, the pellet is resuspended in 20 mM Hepes + 1 mM EDTA, pH 7.4 and homogenized with a 50- ml Dounce homogenizer and again centrifuged. After removing the supernatant, the pellets can be stored at -80°C, until used in binding assay. When used in the assay, membranes are thawed on ice for 20 minutes and then 10 mL of incubation buffer (20 mM Hepes, 1 mM MgCl2, 100 mM NaCl, pH 7.4) added. The membranes are then vortexed to resuspend the crude membrane pellet and homogenized with a Brinkmann PT-3100 Polytron homogenizer for 15 seconds at setting 6. The concentration of membrane protein is determined using the BRL Bradford protein assay.

Please replace the first paragraph on page 267 with the following amended paragraph:

For total binding, a total volume of 50µl~~ul~~ of appropriately diluted membranes (diluted in assay buffer containing 50mM Tris HCl (pH 7.4), 10mM MgCl2, and 1mM EDTA; 5-50µg~~ug~~ protein) is added to 96-well polyproylene microtiter plates followed by addition of 100µl~~ul~~ of assay buffer and 50µl~~ul~~ of **Radiolabelled MCH Ligand**. For nonspecific binding, 50µl~~ul~~ of assay buffer is added instead of 100µl~~ul~~ and an additional 50µl~~ul~~ of 10µM~~uM~~ cold **MCH** is added before 50µl~~ul~~ of **Radiolabelled MCH Ligand** is added. Plates are then incubated at room temperature for 60-120 minutes. The binding reaction is terminated by filtering assay plates through a Microplate Devices GF/C Unifilter filtration plate with a Brandell 96-well plate harvestor followed by washing with cold 50 mM Tris HCl, pH 7.4 containing 0.9% NaCl. Then, the bottom of the filtration plate are sealed, 50 µl of Optiphase Supermix is added to each well, the top of the plates are sealed, and plates are counted in a Trilux MicroBeta scintillation counter. For compound competition studies, instead of adding 100 µl of assay buffer, 100 µl of appropriately diluted test compound is added to appropriate wells followed by addition of 50 µl of Radiolabelled MCH Ligand.